Intelligent Bio Solutions Inc. reported first-quarter fiscal 2027 revenue of $1.39 million, a 25% increase year-over-year and the highest quarterly revenue in company history. Cartridge sales grew 32% to $845,583, representing 61% of total revenue, while gross profit margin expanded to 54.5%. The company also submitted its FDA 510(k) premarket notification for its drug screening system and reported cash and cash equivalents of $5.93 million at the end of the quarter. Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions.
